Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 2/20 | 0.45 |
| ▸ | OPRM1 | P35372 | 6/20 | 0.44 |
| ▸ | DRD3 | P35462 | 3/20 | 0.44 |
| ▸ | DRD4 | P21917 | 2/20 | 0.44 |
| ▸ | DRD2 | P14416 | 1/20 | 0.44 |
| ▸ | CHRM2 | P08172 | 2/20 | 0.41 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.41 |
| ▸ | CHRM3 | P20309 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.40 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.39 |
| ▸ | KIF11 | P52732 | 3/20 | 0.39 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.38 |
| ▸ | GRIN2D | O15399 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11688012 | 0.91 | KIF11 (0.46) | CYP1A2OPRM1DRD3DRD4DRD2 | |
| SCHEMBL6384616 | 0.82 | CYP1A2 (0.48) | CYP1A2OPRM1DRD3DRD4DRD2 | |
| SCHEMBL9780534 | 0.82 | OPRM1 (0.67) | CYP1A2OPRM1DRD3DRD4DRD2 | |
| SCHEMBL395172 | 0.81 | CYP1A2 (0.43) | CYP1A2OPRM1DRD3DRD4DRD2 | |
| SCHEMBL1614867 | 0.81 | CYP2C19 (0.54) | CYP1A2OPRM1DRD3DRD4DRD2 | |
| SCHEMBL379350 | 0.81 | CYP2C19 (0.44) | CYP1A2OPRM1DRD3DRD4DRD2 | |
| Hydrochloric Acid SCHEMBL2861649 | 0.79 | CYP2C19 (0.55) | CYP1A2OPRM1DRD3DRD4DRD2 | |
| Hydrochloric Acid SCHEMBL2395810 | 0.79 | OPRM1 (0.42) | CYP1A2OPRM1DRD3DRD4DRD2 | |
| SCHEMBL7173871 | 0.79 | OPRM1 (0.73) | CYP1A2OPRM1DRD3DRD4DRD2 | |
| SCHEMBL31643504 | 0.78 | OPRM1 (0.41) | CYP1A2OPRM1DRD3DRD4DRD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 99 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2006052985-A1 | LACTONES AS NEW OXYGENATE FUEL ADDITIVES, FUELS BASED THEREON AND METHODS FOR USING SAME | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2006-05-18 | — | — | WO | claimed |
| US-20060096158-A1 | Lactones as new oxygenate fuel additives, fuels based thereon and methods for using same | ROBINSON J M | 2006-05-11 | — | — | US | claimed |
| US-20030069232-A1 | Topical treatment of ocular hypertension, glaucoma, ischemic retinopathy and age-related macular degeneration with ophthalmic formulation of dopamine antagonists | CHIOU GEORGE C Y (US) | 2003-04-10 | — | — | US | claimed |
| EP-1225879-A2 | OPHTHALMIC FORMULATION OF DOPAMINE ANTAGONISTS | Orbon Corporation (US) | 2002-07-31 | — | — | EP | claimed |
| US-20010016604-A1 | Additives enhancing topical actions of therapeutic agents | TRISTRATA, INCORPORATED | 2001-08-23 | — | — | US | claimed |
| WO-2001030337-A2 | OPHTHALMIC FORMULATION OF DOPAMINE ANTAGONISTS | ORBON CORPORATION (US) | 2001-05-03 | — | — | WO | claimed |
| US-6060512-A | Method of using hydroxycarboxylic acids or related compounds for treating skin changes asociated with intrinsic and extrinsic aging | TRISTRATA TECHNOLOGY, INC. (US) | 2000-05-09 | — | — | US | claimed |
| US-5962526-A | ENHANCING THERAPEUTIC EFFECT OT TOPICALLY APPLIED AGENTS | TRISTRATA TECHNOLOGY, INC. (US) | 1999-10-05 | — | — | US | claimed |
| EP-0770399-A2 | Additives enhancing topical actions of therapeutic agents | Van Scott, Eugene J., Dr. (US) | 1997-05-02 | — | — | EP | claimed |
| EP-0273202-B1 | Use of hydroxycarboxylic acids to enhance therapeutic effects of topical compositions for fungal infections and pigmented spots. | SCOTT EUGENE J VAN (US) | 1995-06-21 | — | — | EP | claimed |
| EP-0273202-A2 | Use of hydroxycarboxylic acids to enhance therapeutic effects of topical compositions for fungal infections and pigmented spots. | Van Scott, Eugene J., Dr. (US) | 1988-07-06 | — | — | EP | claimed |
| EP-2688554-A2 | OPTIMISED PREPARATIONS OF HIGHLY ADAPTABLE AGGREGATES | Cevc, Gregor (DE) | 2014-01-29 | — | — | EP | disclosed |
| US-20140017302-A1 | OPTIMISED PREPARATIONS OF HIGHLY ADAPTABLE AGGREGATES | CEVC GREGOR (DE) | 2014-01-16 | — | — | US | disclosed |
| WO-2012126966-A2 | OPTIMISED PREPARATIONS OF HIGHLY ADAPTABLE AGGREGATES | CEVC GREGOR (DE) | 2012-09-27 | — | — | WO | disclosed |
| US-20090023628-A1 | Cosmetic Composition and a Process for Preparing This Cosmetic Composition and a Cosmetic Product | NATURA COSMETICOS S.A. (BR) | 2009-01-22 | — | — | US | disclosed |
| US-5470880-A | Method of using citric acid for the treatment of wrinkles | TRISTRATA, INCORPORATED | 1995-11-28 | — | — | US | disclosed |
| US-5422370-A | Topical application | TRISTRATA, INCORPORATED | 1995-06-06 | — | — | US | disclosed |
| US-5389677-A | Topical application | IGI, INC. | 1995-02-14 | — | — | US | disclosed |
| EP-0599819-A2 | Additives enhancing topical actions of therapeutic agents | Van Scott, Eugene J., Dr. (US) | 1994-06-01 | — | — | EP | disclosed |
| EP-0273202-A2 | Use of hydroxycarboxylic acids to enhance therapeutic effects of topical compositions for fungal infections and pigmented spots. | Van Scott, Eugene J., Dr. (US) | 1988-07-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140017302-A1 | OPTIMISED PREPARATIONS OF HIGHLY ADAPTABLE AGGREGATES | CD68, CHMP4B, ANXA5 | CYP1A2 4605/4885OPRM1 2931/4885DRD3 3937/4885 |
| US-20030069232-A1 | Topical treatment of ocular hypertension, glaucoma, ischemic retinopathy and age-related macular degeneration with ophthalmic formulation of dopamine antagonists | ALDH1A2, SLC6A3, PINK1 | CYP1A2 3690/4885OPRM1 2191/4885DRD3 386/4885 |
| US-20010016604-A1 | Additives enhancing topical actions of therapeutic agents | ALOX15, PLOD3, ALOX15B | CYP1A2 2877/4885OPRM1 4676/4885DRD3 3822/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.